The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | E4412 update: ipi-nivo-brentuximab for R/R Hodgkin lymphoma
Catherine Diefenbach, MD, NYU Langone, New York, NY, gives an update on the extended follow-up of the E4412 trial (NCT01896999), which investigated the combination of ipilimumab, nivolumab and brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
